What did Morgan Stanley do in the latest RHHBY analyst rating update?

On Feb 04, 2026 Morgan Stanley maintained an Underweight on RHHBY and raised its price target to CHF 295 from CHF 290. The move signals continued caution despite a small target increase

How should investors interpret the CHF 295 price target in the RHHBY analyst rating?

CHF 295 is Morgan Stanley’s fair-value estimate under current assumptions. Treat it as one scenario; compare with other analyst targets and Roche’s fundamentals before acting

Does the maintained Underweight mean investors must sell RHHBY?

Not necessarily. Maintained Underweight suggests relative underperformance risk. Long-term or income investors may hold, while traders or benchmark-focused investors might reduce exposure

Where can I read the original analyst note for the RHHBY analyst rating?

The price-target update was reported by TheFly on Feb 04, 2026 and the Q4 2025 earnings transcript is on Seeking Alpha for context, both useful primary sources

Analyst Ratings

Morgan Stanley Maintains Underweight on Roche Holding AG (RHHBY) Feb 2026

ByHuzaifa Zahoor February 5, 2026

Morgan Stanley maintained an Underweight on Roche Holding AG (RHHBY) on Feb 04, 2026, while raising its price target to CHF 295 from CHF 290. The RHHBY analyst rating shows a cautious stance despite the small target increase, and the market reacted with a -1.46% ($-0.84) move on the announcement. We track how a maintained negative bias with a modest target bump fits into broader analyst coverage and what that means for investors weighing Roche against peers